Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis
Tumor necrosis factor (TNF) inhibitors improved clinical outcomes for patients with psoriasis but are limited by their high cost. There are several biosimilar options approved for the treatment of psoriasis which provides a lower-cost alternative and the potential to increase treatment availability...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis Group
2023-12-01
|
| Col·lecció: | Journal of Dermatological Treatment |
| Matèries: | |
| Accés en línia: | http://dx.doi.org/10.1080/09546634.2022.2140569 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|